Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.
As practice-changing diagnostic, therapeutic, and supportive care strategies have entered clinical practice, the 42nd Annual Chemotherapy Foundation Symposium aims to bridge the gap between academic and community oncologists through new education initiatives.
In the next episode of The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, associate professor, Johns Hopkins School of Medicine, and clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital, about what to expect from attending the symposium, as well as places to visit and eat in New York City.
“The importance of this meeting is not only to deliver the educational content in the traditional way, but also really to take CME to another level and start trying to deliver educational content in a novel way, through game shows, through audience participation,” Levy said. “So we're really excited to have this meeting, and right in the heart of New York City, it'll be a wonderful time.”
Levy added that the symposium will highlight education around antibody drug conjugates, diagnostics, novel targeted therapies, and more.
Additional learning objectives will:
CFS, to be held in New York City from November 13-15, 2024, will offer exciting new developments and rapid changes that continue to occur in the management of solid and hematologic malignancies. To learn more about CFS, or to register for the symposium, visit 42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®.
This is just a taste of the wealth of information and inspiration waiting at the 42nd Annual CFS. Check back for future meeting previews with The Show and After Show.
Registration URL: https://event.gotoper.com/BqwM1W?RefId=THC_TSAS
Subcutaneous Daratumumab Significantly Delays Progression in Smoldering Myeloma
December 9th 2024Primary results from the phase 3 AQUILA study showed that subcutaneous daratumumab elicited a significant improvement in PFS compared with active monitoring in patients with smoldering multiple myeloma.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Zilovertamab Vedotin/R-CHP Elicits High Complete Response Rate in DLBCL
Published: December 8th 2024 | Updated: December 8th 2024The addition of zilovertamab vedotin to R-CHP (cyclophosphamide, doxorubicin, prednisone, rituximab) resulted in a 100% complete response rate in patients with previously untreated DLBCL.
Read More